Meeting
2022 ASCO Annual Meeting
Association of LAG-3 expression in circulating T cells and response to combination temozolomide (TMZ) and nivolumab (NIVO) in advanced neuroendocrine neoplasms (NENs): Results from an investigator-initiated phase 2 trial.
Authors
Vineeth Sukrithan
Ohio State University Comprehensive Cancer Center, Columbus, OH
Vineeth Sukrithan , Brooke Benner , Lai Wei , Ashima Goyal , Ye Zhou , Sheryl-Ann Suffren , Carly Pilcher , Gwen Christenson , Nancy Curtis , Emily Schwarz , Himanshu Savardekar , Ruthann Norman , Barbara Kleiber , Robert Wesolowski , Gregory Alan Otterson , Claire F. Verschraegen , William Edgar Carson III, Manisha H. Shah , Bhavana Konda , Dwight Hall Owen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT03728361
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4123)
DOI
10.1200/JCO.2022.40.16_suppl.4123
Abstract #
4123
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy of nivolumab and temozolomide in advanced neuroendocrine neoplasms (NENs) in a phase 2 clinical trial.
First Author: Dwight Hall Owen
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2023 ASCO Annual Meeting
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.
First Author: Nourhan El Ahmar
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
First Author: Omid Hamid